February 2019
Corporate HQ
North Carolina, US

BioAgilytix has scaled its capabilities and geographical reach to become a premier independent global leader in bioanalytical testing, specialising in large molecule bioanalysis, benefitting from a best-in-class bioanalytical lab focusing on enabling all phases of biologics drug development from discovery through to commercial.

In less than three years, GHO completed a number of organic and inorganic investments in specific and strategically compelling areas such as cell & gene therapy, automation capabilities and laboratory information management systems.

BioAgilytix completed three value accretive add-on acquisitions expanding geographic footprint and strategic capabilities into high-value adjacencies.

Value Creation Summary

Enablement & Alignment

Built a global leader in the large molecule industry. A global platform, destination employer with an industry leading customer service rating.

Focus on science-led approach with best-of-breed expertise and capabilities supporting all phases of large molecule global studies. Quality Excellence has remained as #1 priority.

Capability & Capacity

Rapid growth and significant financial performance driven by ~54% CAGR in pipeline and ~36% CAGR in backlog.

Implementation of LIMS and Quality and Compliance electronic systems including electronic document respository and automation to increase efficiency and decrease costs of repeatable laboratory activities.

Expansion of the team with a focus on Business Development organisation, scientific bench and operations both within and outside the US.

Building Strategic Footprints

Completed three value accretive add-on acquisitions: Cambridge BioMedical (Boston), MicroConstants (San Diego), 360biolabs (Australia), expanding geographic footprint and strategic capabilities into high-value adjacencies.

Significant organic and international growth to create a differentiated global leader in large molecule bioanalytical testing

Successfully expanding BioAgilytix's capabilities in the US and Australia via the acquisitions of Cambridge BioMedical, MicroConstants and 360biolabs